Investor Relations
Company Overview
iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.
The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.
Stock Information
Investor Contact Information
Company
iBio Inc.
600 Madison Avenue
Suite 1601
New York, NY 10022
T: 302-355-9452
ir@ibioinc.com
Investor Relations
Stephen Kilmer
T: 646-274-3580
skilmer@ibioinc.com
Transfer Agent
Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000
cstmail@continentalstock.com